Funder
Guangzhou Science and Technology Plan Project
Key Clinical Technique Program of Guangzhou
Publisher
Springer Science and Business Media LLC
Reference101 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. a., & Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492.
2. Shanbhag, S., & Ambinder, R. F. (2018). Hodgkin Lymphoma: A Review and Update on Recent Progress. CA: a cancer journal for clinicians, 68(2), 116–132. https://doi.org/10.3322/caac.21438.
3. Liu, Y., & Barta, S. K. (2019). Diffuse Large B-Cell Lymphoma: 2019 Update on Diagnosis, Risk Stratification, and Treatment. American journal of hematology, 94(5), 604–616. https://doi.org/10.1002/ajh.25460.
4. Reagan, P. M., & Friedberg, J. W. (2017). Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions. Oncology (Williston Park, N.Y.), 31(5), 402–411.
5. Maloney, D. G., Grillo-López, A. J., White, C. a., Bodkin, D., Schilder, R. J., Neidhart, J. a., Janakiraman, N., Foon, K. a., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., & Levy, R. (1997). IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma. Blood, 90(6), 2188–2195.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献